Mon05202019

Robins Global News & Noticias



  • Shipping Advice
    Shipping Advice
  • Featured Guest Post
    Featured Guest Post
  • Featured Guest Post
    Featured Guest Post
  • Featured Guest Post
    Featured Guest Post
  • Trump Pence News
    Trump Pence News
  • Weather Alerts
    Weather Alerts

RobinsPost News Network

+ Larger Font | + Smaller Font

Globe NewsWire News Distribution Service

Press Release: Forty Seven, Inc. to Present Initial Safety and Efficacy Data from Phase 1b Clinical Trial of 5F9 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome at 2019 ASCO Annual Meeting


-- Forty Seven to Host Investor Event and Webcast on June 3, 2019 --
-- Forty Seven Management to Participate in MATTER Panel, The Current and Future Wave of Immuno-Oncology Therapies, on May 30, 2019 --
MENLO PARK, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that promising initial data from its Phase 1b clinical trial evaluating 5F9 as a monotherapy and in combination with azacitidine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) will be presented in a poster discussion session at the 2019 ASCO Annual Meeting in Chicago, Illinois, May 31-June 4, 2019. Presentation Title: The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results
Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Session Date & Time: Monday, June 3, 2019 from 4:30 p.m. – 6:00 p.m. CT (5:30 p.m. – 7:00 p.m. ET)
Abstract Number: 7009
Location: Poster Board #384, Hall A, McCormick Place
The accepted abstract is now available online on the ASCO website: https://iplanner.asco.org.Forty Seven’s Phase 1b clinical trial evaluating 5F9 as a monotherapy and in combination with azacitidine for the treatment of AML and MDS is funded in part by a research grant awarded by the California Institute for Regenerative Medicine (CIRM).Investor Event and Webcast InformationForty Seven will host an investor event on Monday, June 3, 2019 beginning at 6:30 p.m. CT (7:30 p.m. ET) in Chicago to review the initial clinical data presented at ASCO for 5F9. The event will be webcast live and can be accessed under “Events & Presentations” in the Investors section of the Forty Seven website at www.fortyseveninc.com. A replay of the webcast will be available approximately two hours after the event and will be available for ...


Posted: 2019-05-15 21:01:00

Get Full News Story On GlobeNewsWire Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.


Print Friendly and PDF Share Embed


Related News Stories From The Web And More

Related Bing News

Press Release: Forty Seven, Inc. to Present Initial Safety and Efficacy Data from Phase 1b Clinical Trial of 5F9 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome at 2019 ASCO Annual Meeting | Globe NewsWire News Distribution Service | RobinsPost News Network - Newscast

Takeda Expands Oncology Research, Demonstrating Commitment to Patient Community at 15th International Symposium on Myelodysplastic Syndromes

Wed, 15 May 2019 03:36:00 GMT

These findings are an important aspect of our work as we strive to bring new treatment options to patients ... Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myeloid ...

Does Chemotherapy Increase the Risks of Myelodysplastic Syndrome and Acute Myeloid Leukemia?

Thu, 07 Feb 2019 08:46:00 GMT

Receipt of chemotherapy was associated with a 1.5-fold to more than 10-fold higher risk of developing therapy-related myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML ... been reported ...

Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes

Thu, 17 Jan 2019 06:38:00 GMT

Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation ... Clinical utility of next-generation sequencing for oncogenic mutations in patients with acute myeloid leukemia ...

How does acute myeloid leukemia (AML) develop in patients exposed to chemotherapy agents?

Tue, 04 Dec 2018 16:00:00 GMT

[Medline]. Cortes JE, et al. A phase 2 randomized study of low dose Ara-C with or without glasdegib (PF-04449913) in untreated patients with acute myeloid leukemia or high-risk myelodysplastic ...

Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level

Mon, 03 Dec 2018 08:06:00 GMT

Myelodysplastic syndromes (MDS) frequently progress to acute myeloid leukemia (AML); however ... we studied highly fractionated stem cell populations in longitudinal samples of patients with MDS who ...

Related Bing Web Search

Acute myeloid leukemia - Wikipedia

(Fri, 17 May 2019 20:49:00 GMT)

Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cells. Symptoms may include feeling tired, shortness of breath, easy bruising and bleeding, and increased risk of infection. Occasionally, spread may occur to the brain, skin, or gums.

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome - Full Text View - ClinicalTrials.gov

(Wed, 15 May 2019 15:08:00 GMT)

This randomized phase II/III trial studies how well azacitidine with or without nivolumab or midostaurin, or decitabine and cytarabine alone work in treating older patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome | Leukemia - nature.com

(Wed, 15 May 2019 14:46:00 GMT)

Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are clinically and genetically heterogeneous myeloid stem cell disorders with a median age at onset of about 67 years [].Older ...

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes | NEJM

(Tue, 20 Oct 2009 23:56:00 GMT)

BackgroundThe molecular determinants of clinical responses to decitabine therapy in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) are unclear. MethodsWe enrolled 84 ...

A Biomarker-Directed Phase 2 Trial of SY-1425 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome - ClinicalTrials.gov

(Mon, 20 Jun 2016 23:53:00 GMT)

The purpose of this study is to determine the activity of SY-1425 in relapsed/refractory acute myeloid leukemia (AML) patients, relapsed/refractory higher-risk myelodysplastic syndrome (MDS) patients (SY-1425 administered as a monotherapy or in combination with daratumumab), newly diagnosed ...

Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Patient Version - Comprehensive Cancer Information - National Cancer Institute

(Wed, 20 Feb 2019 09:52:00 GMT)

Childhood acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes a large number of abnormal blood cells. Childhood acute myeloid leukemia (AML) is a cancer of the blood and bone marrow.AML is also called acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, and acute nonlymphocytic leukemia.

Adult Acute Myeloid Leukemia Treatment (PDQ®)—Patient Version - National Cancer Institute

(Tue, 02 Oct 2018 22:12:00 GMT)

Adult acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets. Enlarge Anatomy of the bone. The bone is made up of compact bone, spongy bone, and bone marrow. Compact bone makes up the outer ...

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia | Blood Journal

(Thu, 06 Jul 2017 23:53:00 GMT)

Introduction. Acute myeloid leukemia (AML) commonly affects the elderly, with a median age of 67 years at diagnosis. 1 Elderly patients (≥65 years) with AML often respond poorly to induction chemotherapy as a result of a higher frequency of adverse genomic features and increased resistance to treatments. 2 Furthermore, because of comorbidities, compromised organ function, and poor ...

Risk Factors for Acute Myeloid Leukemia (AML)

(Mon, 20 Aug 2018 23:53:00 GMT)

A risk factor is something that affects your chance of getting a disease, such as cancer. Different cancers have different risk factors. Some risk factors, like smoking, can be changed. Others, like a person’s age or family history, can’t be changed. But having a risk factor, or even several ...

Rare Disease Database - Acute Myeloid Leukemia - NORD (National Organization for Rare Disorders)

(Fri, 17 May 2019 08:24:00 GMT)

Acute myeloid leukemia is the most common form of acute leukemia in adults, making up about 80% of people with acute leukemia. In the United States, it is estimated that 3-5 people per every 100,000 people in the general population has the disease.

Related News Story Videos From Youtube

Leukemia AML MDS Moon Shots update


Related Videos On: Leukemia AML MDS Moon Shots update


Acute Myeloid Leukemia | Clinical Presentation


Related Videos On: Acute Myeloid Leukemia | Clinical Presentation


Acute Myeloid Leukemia (AML)


Related Videos On: Acute Myeloid Leukemia (AML)


Clinical Trial Results of New Agent for Myelodysplastic Syndromes and Acute Myeloid Leukemia


Related Videos On: Clinical Trial Results of New Agent for Myelodysplastic Syndromes and Acute Myeloid Leukemia


Young cancer survivor endures three transplants to beat AML


Related Videos On: Young cancer survivor endures three transplants to beat AML






Blow Us A Whistle

Comments (Whistles) Designed By Disqus




Company Information

Official Content Providers











PRIVACY POLICY

We recommend Firefox 3 (and above), Edge, and Chrome for dynamic performance.
© 2008-2019 RobinsPost (The Bird's Eye View Company) All rights are reserved.
RobinsPost provides links to news sites based on their RSS feeds.
All trademarks, copyrights, videos, photos and logos are owned by news sources.
News stories, videos and live streams are from trusted sources:
Bing News, Google News, NewsApi.org and YouTube Search Results.
ROBINSPOST Is Proudly Made In America.
Where Quality, Safety and Service Comes First.